SA
Log In
VKTX
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
24 analysts·High coverage
75
Score
23 Buy (96%)1 Hold (4%)0 Sell (0%)
Rating Breakdown
Strong Buy
14%
Buy
2292%
Hold
14%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$95.00
+208.9%
Consensus
$100.50
+226.8%
Bull
$107.00
+248.0%
12-Month Target Range24 analysts
$95.00$100.50$107.00
Current $30.75Consensus
Current Price
$30.75
Upside to Consensus
$69.75

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+2.53%
EPS—
FY2028
Rev+1622.31%
EPS—
FY2029
Rev+218.98%
EPS—

Earnings Surprises

Recent Analyst Actions

Apr 30, 2026Morgan Stanley
Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley
Target:$95.00
+212.7%from $30.39
Apr 30, 2026Cantor Fitzgerald
Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald
Target:$100.00
+219.2%from $31.33
Mar 12, 2026Jefferies
Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this year"
Target:$101.00
+184.7%from $35.47
Feb 12, 2026Morgan Stanley
Viking Therapeutics price target lowered to $99 from $102 at Morgan Stanley
Target:$99.00
+218.6%from $31.07
Nov 12, 2025Canaccord Genuity
Viking Therapeutic (VKTX) PT Raised to $107 at Canaccord Genuity
Target:$107.00
+163.5%from $40.60
Oct 29, 2025Canaccord Genuity
Canaccord starts Viking Therapeutics with Buy on obesity potential
Target:$106.00
+203.5%from $34.93
Oct 23, 2025Morgan Stanley
Viking Therapeutics price target raised to $102 from $98 at Morgan Stanley
Target:$102.00
+224.6%from $31.42
Oct 23, 2025Cantor Fitzgerald
Viking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald
Target:$105.00
+234.2%from $31.42
Apr 28, 2025Truist Financial
Viking Therapeutics price target lowered to $75 from $95 at Truist
Target:$75.00
+189.1%from $25.94
Dec 2, 2024Piper Sandler
Piper Sandler Starts Viking Therapeutic (VKTX) at Overweight
Target:$74.00
+39.8%from $52.94
Nov 4, 2024Laidlaw
Laidlaw Reiterates Buy Rating on Viking Therapeutic (VKTX)
Target:$110.00
+74.2%from $63.14
Nov 4, 2024Jefferies
Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX)
Target:$110.00
+74.2%from $63.14
Jun 27, 2024Morgan Stanley
Viking Therapeutics initiated with an Overweight at Morgan Stanley
Target:$105.00
+121.6%from $47.39
Jun 25, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
Target:$90.00
+72.7%from $52.12
May 16, 2024Raymond James
Raymond James Upgrades Viking Therapeutic (VKTX) to Strong Buy
Target:$116.00
+68.0%from $69.06
May 16, 2024Truist Financial
Roche data falls short of Viking weight loss drug, says Truist
Target:$120.00
+72.6%from $69.53
Mar 26, 2024Oppenheimer
Viking Therapeutic (VKTX) PT Raised to $138 at Oppenheimer
Target:$138.00
+70.7%from $80.83
Mar 26, 2024BTIG
Viking Therapeutic (VKTX) PT Raised to $125 at BTIG
Target:$125.00
+48.8%from $83.98
Mar 26, 2024Stifel Nicolaus
Viking Therapeutic (VKTX) PT Raised to $95 at Stifel
Target:$95.00
+13.3%from $83.87
Mar 15, 2024BTIG
Viking Therapeutic (VKTX) PT Raised to $100 at BTIG
Target:$100.00
+59.8%from $62.56
Dec 24, 2022Maxim Group
Viking Therapeutics (VKTX) Stock Gets A $15 Price Target
Target:$15.00
+77.5%from $8.45
Dec 19, 2022BTIG
Madrigal's data bodes well for Viking's de-risked VK2809, says BTIG
Target:$20.00
+197.6%from $6.72
Dec 19, 2022H.C. Wainwright
Madrigal data 'great readthrough' for Viking, says H.C. Wainwright
Target:$21.00
+229.9%from $6.37

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance